Newsroom

March 25, 2019

Ambry Genetics to Develop Custom Assays Targeted to Patients with Hereditary Ovarian Cancer

Investigating new testing options to identify patients for clinical trials

Aliso Viejo, CA (March 13, 2019); Ambry Genetics, a Konica Minolta Company (Ambry), and leading provider of clinical and research genetic testing, today announced a new laboratory services agreement with Clovis Oncology Inc., a biopharmaceutical company which shares Ambry’s commitment to advancing precision medicine for cancer.  Through this laboratory services agreement, Ambry Genetics and Clovis Oncology seek to identify clinical trial patients who may benefit from Rubraca®, a therapy currently approved in the U.S. and Europe in multiple advanced ovarian cancer settings.

Approximately 10 to 15% of ovarian cancer diagnoses are based on hereditary mutations of BRCA, meaning they are directly linked to mutations in the BRCA1 or BRCA2 genes passed on from a parent. Ambry’s genetic tests can identify mutations in these two genes, as well as related genes involved in the DNA repair pathway, thus enabling identification of potential risk, earlier diagnosis and more precise treatment. 

"We are very excited to be working with the Clovis team, which is aligned with our precision medicine initiatives,” said Brigette Tippin Davis, Ph.D., FACMG, Senior Vice President of Research & Development of Ambry Genetics, Inc. “Our mission is to help identify patients eligible for optimal therapies to improve outcomes and enhance quality of life.”

Clovis chose to perform retrospective BRCA testing with Ambry Genetics, a high-quality genetics lab positioned to become a key player in the precision medicine space.

Press Contact:
Jackie Copp
Jackie@PitchPublicRelations.com
480.606.8180

About Konica Minolta Precision Medicine

Konica Minolta Precision Medicine, Inc. (“KMPM”) based in Aliso Viejo, CA is a subsidiary of Konica Minolta, Inc. that includes Ambry Genetics Corporation and Invicro LLC. Founded in 2018 on the belief that groundbreaking medical breakthroughs are possible by concentrating efforts on the health expression map, the undiscovered territory between an individual’s genetics and biological impacts, and quantifiably measuring health over time. KMPM’s health intelligence and visualization platform brings together the most novel and diverse set of data from genes, proteins, cells and tissues with sophisticated analytics and world-leading scientific and medical expertise, enabling more prescriptive, proactive and preventive care. For further information, visit: KonicaMinoltaPrecisionMedicine.com

Press Contact:
Olivia Duarte
press@ambrygen.com
(949) 457-4335